- This is Chamath Palihapitiya's controversial SPAC that went down on lawsuit news
- Bullish breakout is imminent after unfair bearish beatdown
- RSI is oversold so we should start seeing a reversal
$CLOV merged with $IPOC (Chamath’s SPA). Chamath’s track record speaks for itself. His investments including SPCE, OPEN, and his other current PIPE investment have all done really well and are quality companies. Since the merger with Clover Health, Chamath upped his stake in the Clover Health and now owns roughly 30%
- Medicare Advantage spending was $270 billion in 2019, and is expected to expand to $590 billion by 2025.
- As of now $CLOV is only in 34 counties that has generated them 507M in revenue.
- They already are expanding and will be in 108 counties which will take their revenue to just shy of a billion.
- There’s 3,000 counties in the US. Being in 108 counties is just 0.03% penetration of the total addressable market
- Cost Savings: They’ve proven to build Medicare Advantage plans that balance quality and cost. They’re fixated on how they can deliver the lowest cost possible. Any business obsessed with delivering value and cost savings to consumers is always successful.
- Partnerships: Walmart, CVS, Walgreens, Kroger, Costco. But wait, that’s not all they do.
- Competitive Advantage: In addition to their Medicare business, the other side of the business (that can be leveraged in conjunction to their Medicare plans) is called Clover Assistant. This is their proprietary AI focused and data driven software. It allows doctors to leverage historical patient data in order to create more effective treatment plans. This results in lowered costs, fewer visits, and better outcomes for everyone involved.
FY 2020 Financial Results
- Grew total revenue 46% year-over-year to $673 million in 2020
- Surpassed 32,400 Lives under Clover Assistant management at year end, a 43% increase year-over-year